CA-LATTICEFLOW-AI
LatticeFlow AI, the leading platform empowering Artificial Intelligence (AI) teams to build performant, safe, and trustworthy AI solutions, proudly announces that it has joined the U.S. AI Safety Institute Consortium (AISIC). LatticeFlow AI researchers will support Working Group #3, focusing on capability evaluations. Together with the National Institute of Standards & Technology (NIST) and other consortium members, LatticeFlow AI will support the development of methods, benchmarks, and testing environments that help organizations operationalize the practices outlined in NIST’s AI Risk Management Framework (RMF).
Dave Henry, SVP of Business Development at LatticeFlow AI, added: “AI safety programs are interdisciplinary in nature, requiring a broad range of management and technical skills to execute. The Consortium brings diverse experts together to create durable and innovative practices that promote trustworthy AI. We look forward to contributing our knowledge of AI model safety and collaborating on new approaches for scalable evaluations.”
Executive Demand for Trustworthy AI
Despite the impressive accuracy of AI models demonstrated in pilots and proof-of-concept projects, building AI solutions that perform reliably on real-world data remains an immense challenge. This affects both technical teams building and delivering AI solutions as well as management teams that need to quantify risks and approve AI solutions for use in business-critical operations. As a result, 85% of the models never make it into production, and out of those that do, 91% degrade over time.
“Unfortunately, high-value AI deployments are being delayed due to developer delay, insufficient good data governance and the inability to quantify possible risks associated with the use of their AI models,” stated Randolph Kahn Esq., President of Kahn Consulting Inc. “Consortiums such as AISIC can produce detailed guidelines and best practices, and when coupled with LatticeFlow AI’s technology, this can lead to a significant reduction of the time and cost required to complete thorough risk assessments and unlock the value of AI systems.”
The U.S. AI Safety Institute Consortium
AISIC was established by the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) to contribute to the priority actions outlined in U.S. President Biden’s Executive Order on the Safe, Secure, and Trustworthy Development and Use of AI. These include developing red-teaming guidelines, technical assessment standards, and risk management practices, among other key elements to the development of trustworthy AI and its responsible use.
LatticeFlow AI's Contributions to Making AI Safe and Trustworthy
LatticeFlow AI’s association with AISIC follows a series of contributions made by the LatticeFlow AI team towards the goals outlined by AISIC and President Biden’s Executive Order. Since 2020, LatticeFlow AI has been an invited technical contributor to key AI Safety initiatives at the International Organization for Standardization, where it has actively contributed to the working group focusing on the development and standards for Trustworthy AI. Earlier this year, LatticeFlow AI hosted renowned AI leaders at the World Economic Forum’s AI House, gathering key figures in AI, including Gary Marcus (NYU), Apostol Vassilev (NIST), Kai Zenner (European Parliament), Matthias Bossardt (KPMG), Thomas Stauner (BMW), among other industry experts, to delve into the latest AI developments and discuss responsible AI adoption.
From Standards to Practice: First AI Assessment for a Leading Swiss Bank
Moving beyond the development of AI guidelines and standards, this year, LatticeFlow AI announced the first industry-pioneering technical AI Assessment for Migros Bank, a leading Swiss Bank, demonstrating how these AI standards are used in practice to mitigate risk and ensure regulatory compliance for business-critical AI solutions. The results of this assessment, alongside a concrete blueprint to implement AI governance and technical AI assessments at enterprises and governments, were presented at a dedicated event hosted at the ETH AI Center.
LatticeFlow AI’s Commitment to the U.S. and NIST’s AI Safety Institute Consortium
With its contributions to AISIC, LatticeFlow AI will continue its commitment to helping U.S. government agencies such as the U.S. Army ensure the safety and trustworthiness of mission-critical AI systems. Last year, White House officials announced LatticeFlow AI as the first-place winner in the “red teaming” AI Privacy Prize Challenge category. Subsequently, the company announced a strategic expansion towards the US and a three-year strategic engagement with the U.S. Army to build next-generation resilient AI solutions for mission-critical defense use cases.
"Joining AISIC will allow us to accelerate and broaden our impact by aligning our efforts towards ensuring AI trust and safety with global AI leaders, enterprises, and governments," said Petar Tsankov, Co-founder and CEO of LatticeFlow AI.
Interested in learning more?
- Watch the replay of our event on AI Governance & Audits: Navigating AI Risks and Compliance.
- Visit our web page to learn how to manage your AI model risk with comprehensive technical AI assessments.
- If you are interested in conducting an AI assessment, book a meeting with a LatticeFlow AI expert.
About LatticeFlow AI
LatticeFlow AI offers a cutting edge AI platform that empowers enterprise teams to build performant, safe, and trustworthy AI at scale. Our platform is designed to unlock the full value of AI by systematically addressing critical model and data issues through automated processes and intelligent workflows across your entire AI lifecycle.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423153331/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
